ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
STA Pharmaceutical and BioLingus will collaborate on development and marketing of sublingual drug delivery techniques. STA, the contract development and manufacturing division of China’s WuXi AppTec, will have exclusive access to BioLingus’s technology for under-the-tongue delivery of drugs—including small molecules, peptides, and proteins—currently administered via injection. BioLingus says its technology is inspired by how plants keep proteins stable in their seeds over long periods of time.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter